Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Seasonal affective disorder (SAD) has been recognized and included in the diagnostic classification system of the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, as a major depressive disorder with seasonal pattern. Seasonality, means changing weathers highly affects people all over the world. Moreover, increasing incidence of seasonal affective disorder is expected to boost the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that around 14% of the adult in the U.S. population suffers from a lesser form of seasonal mood changes, known as winter blues.

The global seasonal affective disorder market is estimated to be valued at US$ 544.7 million in 2020 and is expected to exhibit a CAGR of 5.5% during the forecast period (2020-2027).

Figure 1. Global Seasonal Affective Disorder Market Share (%), by Region, 2020

Seasonal Affective Disorder  | Coherent Market Insights

Increasing cases of seasonal affective disorder is expected to propel growth of the global seasonal affective disorder market

The increasing cases of seasonal affective disorder is expected to boost the market growth over the forecast period. For instance, according to an article published by the Royal College of Psychiatrists, in April 2015, reports that around 3 out of 100 people have significant winter depressions in the U.K.

However, side effects of seasonal affective disorder medication such as Bupropion is expected to hinder the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that the drug Bupropion, which is approved by the U.S. FDA exhibit several side effects such as ophthalmologic including blurred vision; central nervous system including insomnia, headache, agitation, dizziness; dermatologic such as diaphoresis, and others.

request-sample

Seasonal Affective Disorder Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 544.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.5% 2027 Value Projection: US$ 794.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Fall & Winter Seasonal Affective Disorder, Spring & Summer Seasonal Affective Disorder, Others.
  • By Treatment: Light Therapy, Medications, Psychotherapy, Counselling, Others.
  • By End User: Hospitals, Clinics, Research Institutes, Others.
Companies covered:

Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc.

Growth Drivers:
  • Rising incidence of seasonal affective disorder
  • Increasing product approval for the treatment of seasonal affective disorder
Restraints & Challenges:
  • Side-effects of seasonal affective disorder medications

Figure 2. Global Seasonal Affective Disorder Market Share (%), by Type, 2020

Seasonal Affective Disorder  | Coherent Market Insights

Increasing cases of seasonal affective disorder (SAD) in North America is expected to boost the market growth

North America is expected to hold dominant position in the global seasonal affective disorder market, owing to increasing cases of seasonal affective disorder (SAD) in the region. For instance, according to an article published by the Boston University, in October 2019, reports that 10 million U.S. populace are affected by seasonal affective disorder, with women 4 times more likely to be diagnosed than men.

Global Seasonal Affective Disorder Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global seasonal affective disorder market during the forecast period.

Key Players

Major players operating in the global seasonal affective disorder market include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc., among others.

Seasonal affective disorder (SAD) is a form of depression that people experience at a particular time of year or during a particular season. The change in the season highly affects the mood and energy levels, and lead to symptoms of depression that have a significant impact on day-to-day life.

Market Dynamics

Rising incidence of seasonal affective disorder (SAD) is expected to drive seasonal affective disorder market growth over the forecast period. For instance, according to an article published by the Hindawi Publishing Corporation-Depression Research and Treatment, in December 2015, reports that the people who lives farthest from the equator in northern latitudes are most susceptible towards SAD, for instance, in the U.S., 1.4% of those who live in Florida and 9.9% living in Alaska experience seasonal affective disorder.

However, side effects of seasonal affective disorder medication such as Bupropion is expected to hinder the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that the drug Bupropion, which is approved by the U.S. FDA exhibit several side effects such as tachycardia (cardiovascular disease), rhinitis and pharyngitis (respiratory diseases), and others.

Key features of the study:

  • This report provides in-depth analysis of the global seasonal affective disorder market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global seasonal affective disorder market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., AbbVie, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global seasonal affective disorder market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global seasonal affective disorder market.

Detailed Segmentation:

  • Global Seasonal Affective Disorder Market, By Type:
    • Fall & Winter Seasonal Affective Disorder
    • Spring & Summer Seasonal Affective Disorder
    • Others
  • Global Seasonal Affective Disorder Market, By Treatment:
    • Light Therapy
    • Medications
    • Psychotherapy
    • Counselling
    • Others
  • Global Seasonal Affective Disorder Market, By End User:
    • Hospitals
    • Clinics
    • Research Institutes
    • Others
  • Global Seasonal Affective Disorder Market, By Region:
    • North America
      • By Type:
        • Fall & Winter Seasonal Affective Disorder
        • Spring & Summer Seasonal Affective Disorder
        • Others
      • By Treatment:
        • Light Therapy
        • Medications
        • Psychotherapy
        • Counselling
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • Fall & Winter Seasonal Affective Disorder
        • Spring & Summer Seasonal Affective Disorder
        • Others
      • By Treatment:
        • Light Therapy
        • Medications
        • Psychotherapy
        • Counselling
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Fall & Winter Seasonal Affective Disorder
        • Spring & Summer Seasonal Affective Disorder
        • Others
      • By Treatment:
        • Light Therapy
        • Medications
        • Psychotherapy
        • Counselling
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Fall & Winter Seasonal Affective Disorder
        • Spring & Summer Seasonal Affective Disorder
        • Others
      • By Treatment:
        • Light Therapy
        • Medications
        • Psychotherapy
        • Counselling
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • Fall & Winter Seasonal Affective Disorder
        • Spring & Summer Seasonal Affective Disorder
        • Others
      • By Treatment:
        • Light Therapy
        • Medications
        • Psychotherapy
        • Counselling
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Fall & Winter Seasonal Affective Disorder
        • Spring & Summer Seasonal Affective Disorder
        • Others
      • By Treatment:
        • Light Therapy
        • Medications
        • Psychotherapy
        • Counselling
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • Research Institutes
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline plc
    • Johnson & Johnson Services Inc.
    • Novartis AG
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lily and Company
    • AbbVie Inc.
    • Hoffmann-La Roche AG
    • Mylan, Inc.
    • Bausch Health
    • Koninklijke Philips N.V.
    • Bayer AG
    • Allergan
    • Bristol-Myers Squibb
    • Henry Schein Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Treatment
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Seasonal Affective Disorder Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Seasonal Affective Disorder Products
  5. Global Seasonal Affective Disorder Market, By Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Fall & Winter Seasonal Affective Disorder
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Spring & Summer Seasonal Affective Disorder
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Seasonal Affective Disorder Market, By Treatment, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Light Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Medications
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Psychotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Counselling
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Seasonal Affective Disorder Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Research Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Seasonal Affective Disorder Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson Services Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lily and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bausch Health
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Koninklijke Philips N.V.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Allergan
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Henry Schein Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 42 market data tables and 38 figures on "Seasonal Affective Disorder Market” - Global forecast to 2027

FAQgrowicon

Frequently Asked Questions

The global seasonal affective disorder market is expected to exhibit a CAGR of 5.5% during the forecast period (2020-2027).
The global seasonal affective disorder market is estimated to be valued at US$ 544.7 million in 2020.
Rising incidence of seasonal affective disorder are favoring the market growth.
Fall & winter seasonal affective disorder segment is expected to be the leading type segment in the global seasonal affective disorder market during the forecast period (2020-2027).
North America seasonal affective disorder market is expected to generate highest revenue share during the forecast period.
Major players operating in the global seasonal affective disorder market include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc., among others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.